Trial · NCT05681884
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Primary Objective | 48 weeks | Analyze the change in the area of retinal non-perfusion (RNP) within the macula over 48 weeks using ultrawide-field fluorescein angiography (UWFA) within eyes that have NPDR. |
| Primary | Primary Objective | 48 weeks | Analyze the change in the area of retinal non-perfusion (RNP) outside the macula over 48 weeks using ultrawide-field fluorescein angiography (UWFA) within eyes that have NPDR. |
| Secondary | Change in area of RNP | Baseline through week 96 | Change in area of RNP, as assessed by a central reading center; linear regression of change in area of RNP (dependent variable) between the monthly faricimab and observation groups, adjusted for age, sex, and disease severity as defined by Baseline ETDRS |
| Secondary | Change in area of RNP within the macula | Baseline through week 48 and from baseline through week 96 | Change in area of RNP within the macula, as assessed by ultrawide-field fluorescein; linear regression of change in area of RNP (dependent variable) between the monthly faricimab and observation groups, adjusted for age, sex, and disease severity as defined by Baseline ETDRS |
| Secondary | Change in area of RNP outside of the macula | Baseline through week 48 and from baseline through week 96 | Change in area of RNP outside of the macula, as assessed by ultrawide-field fluorescein from baseline to week 96; linear regression of change in area of RNP (dependent variable) between the monthly faricimab and observation groups, adjusted for age, sex, and disease severity as defined by Baseline ETDRS |
| Secondary | Percentage of subjects with disease | Baseline through week 96 | Percentage of subjects with neovascularization and/or vitreous hemorrhage and/or DME |
| Secondary | Mean change in ETDRS | Baseline through week 48 and from baseline through week 96 | Mean change in ETDRS BCVA |
| Secondary | Mean change in CST | Baseline through week 48 and from baseline through week 96 | Mean change in CST |
| Secondary | Contrast Sensitivity | Baseline through Week 48 and from baseline through week 96 | Contrast sensitivity as measured using the quantitative Contrast Sensitivity Function (qCSF) testing on the Manifold Contrast Vision |
| Secondary | Natural History of RNP | Baseline through Week 48 and from baseline through week 96 | Natural history of RNP through detection of apoptosing retinal cells (DoARC) imaging |
| Secondary | 2-step Improvement in DRSS | 48 weeks and 96 weeks | Proportion of subjects with at least a 2-step improvement in DRSS |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05681884/registered